Managing Breakthrough Disease in Multiple Sclerosis Patients
Author Information
Author(s): Prosperini Luca, Borriello Giovanna, De Giglio Laura, Leonardi Laura, Barletta Valeria, Pozzilli Carlo
Primary Institution: Multiple Sclerosis Centre, Dept. of Neurology and Psychiatry, S. Andrea Hospital, Sapienza University, Rome, Italy
Hypothesis
Does switching from low-dose to high-dose Interferon beta improve clinical outcomes in patients with breakthrough disease?
Conclusion
Switching to high-dose Interferon beta did not significantly reduce the risk of relapses or disability progression in most patients over two years.
Supporting Evidence
- 59.5% of patients had a relapse after switching to high-dose Interferon beta.
- 42.1% of patients experienced sustained progression on the EDSS score.
- Patients switched due to MRI activity had a lower relapse rate compared to those switched due to clinical relapses.
Takeaway
The study looked at patients with multiple sclerosis who switched to a higher dose of medication but found that most still had problems with their disease.
Methodology
This was a 2-year observational study of patients with relapsing-remitting MS who switched to high-dose Interferon beta due to relapses or MRI activity.
Potential Biases
Potential biases due to the observational nature and lack of randomization.
Limitations
The study was observational, lacked a control group, and had a small sample size.
Participant Demographics
{"male_percentage":32.2,"mean_age":31.5,"mean_ms_duration":5.4}
Statistical Information
P-Value
0.001
Confidence Interval
95% C.I. 2.22 - 13.85
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website